Expert opinion on pharmacotherapy

Keyphrases

Publications

volume 25, number 7, 2024

Teruo Jojima, Shintaro Sakurai, Haruka Kishi, Kananko Kato, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa Aso
Empagliflozin increases plasma levels of citrulline, histidine, and α-aminobutyric acid in patients with type 2 diabetes: effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profile. Expert opinion on pharmacotherapy 25 (7) (2024)
Hoang Nam Pham, Linh Pham, Keisaku Sato
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis. Expert opinion on pharmacotherapy 25 (7) (2024)
Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, null Nidhi
Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Expert opinion on pharmacotherapy 25 (7) (2024)
Eiji Higashihara, Takeo Harada, Hiroshi Fukuhara
Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease. Expert opinion on pharmacotherapy 25 (7) (2024)
Andrew Gaballa, Shada Jadam, Milind Y Desai
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond. Expert opinion on pharmacotherapy 25 (7) (2024)
Amanda M Acuña, Connor Park, Jonna M Leyrer-Jackson, M Foster Olive
Promising immunomodulators for management of substance and alcohol use disorders. Expert opinion on pharmacotherapy 25 (7) (2024)
Ann C Childress
Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. Expert opinion on pharmacotherapy 25 (7) (2024)
Krystyna Dobrowolska, Michał Brzdęk, Piotr Rzymski, Robert Flisiak, Małgorzata Pawłowska, Jakub Janczura, Kinga Brzdęk, Dorota Zarębska-Michaluk
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert opinion on pharmacotherapy 25 (7) (2024)
Daniel Lee, Inga M Antonsdottir, Emily D Clark, Anton P Porsteinsson
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential. Expert opinion on pharmacotherapy 25 (7) (2024)
Prathima Gogineni, Eka Melson, Dimitris Papamargaritis, Melanie Davies
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert opinion on pharmacotherapy 25 (7) (2024)
Marlene Hager, Tal Goldstein, Victoria Fitz, Johannes Ott
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms. Expert opinion on pharmacotherapy 25 (7) (2024)
Daniel Lee, Inga M Antonsdottir, Emily D Clark, Anton P Porsteinsson
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential. Expert opinion on pharmacotherapy 25 (7) (2024)
Gabriele Roccuzzo, Andrea Roggo, Egle Ramelyte, Sara Marchisio, Chiara Astrua, Simone Ribero, Julia Scarisbrick, Paolo Fava, Pietro Quaglino
Advances in the pharmacological management of cutaneous T-cell lymphoma. Expert opinion on pharmacotherapy 25 (7) (2024)
Andrew Gaballa, Shada Jadam, Milind Y Desai
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond. Expert opinion on pharmacotherapy 25 (7) (2024)

volume 25, number 8, 2024

Sofia Pitsiava, Georgios Dimakopoulos, Vasilis Tsimihodimos, Kalliopi Kotsa, Theocharis Koufakis
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study. Expert opinion on pharmacotherapy 25 (8) (2024)
Ginny Carter, Sarah McGlothlin, Skye McLaurin-Jiang, Rebecca B Carlson, Kevin E O'Grady, Hendree E Jones
The effects of prenatal exposure to opioids on early childhood development: context matters most. Expert opinion on pharmacotherapy 25 (8) (2024)
Avinash Tiwari
Upadacitinib in Crohn's disease: needs more insight. Expert opinion on pharmacotherapy 25 (8) (2024)
Rossella Laitano, Luigino Calzetta, Matteo Matino, Elena Pistocchini, Rogliani Paola
Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement. Expert opinion on pharmacotherapy 25 (8) (2024)
Kyaw Oo, Saad Ahmed, Lily Snell, Syed Haider Tahir, Hasan Tahir
An update in the pharmacological management of axial spondyloarthritis. Expert opinion on pharmacotherapy 25 (8) (2024)
May N Samimi, Andrew Hale, Jessica Schults, Andreas Fischer, Jason A Roberts, Jayesh Dhanani
Clinical guidance for unfractionated heparin dosing and monitoring in critically ill patients. Expert opinion on pharmacotherapy 25 (8) (2024)
Geeta Ilipilla, L Eugene Arnold
The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. Expert opinion on pharmacotherapy 25 (8) (2024)
Piercarlo Sarzi-Puttini, Valeria Giorgi, Silvia Sirotti, Laura Bazzichi, Daniela Lucini, Simona Di Lascio, Greta Pellegrino, Diego Fornasari
Pharmacotherapeutic advances in fibromyalgia: what's new on the horizon? Expert opinion on pharmacotherapy 25 (8) (2024)
Christian D Harding, Ana Lucia Fuentes, Atul Malhotra
Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance. Expert opinion on pharmacotherapy 25 (8) (2024)
Christian D Harding, Ana Lucia Fuentes, Atul Malhotra
Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance. Expert opinion on pharmacotherapy 25 (8) (2024)
Piercarlo Sarzi-Puttini, Valeria Giorgi, Silvia Sirotti, Laura Bazzichi, Daniela Lucini, Simona Di Lascio, Greta Pellegrino, Diego Fornasari
Pharmacotherapeutic advances in fibromyalgia: what's new on the horizon? Expert opinion on pharmacotherapy 25 (8) (2024)
Christian D Harding, Ana Lucia Fuentes, Atul Malhotra
Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance. Expert opinion on pharmacotherapy 25 (8) (2024)
Olga Biniszewska, Damian Jacenik, Aleksandra Tarasiuk, Jakub Fichna
Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome. Expert opinion on pharmacotherapy 25 (8) (2024)
Sebastiano Leone, Ilaria Pezone, Mariantonietta Pisaturo, Eleni McCaffery, Aniello Alfieri, Marco Fiore
Pharmacotherapies for multidrug-resistant gram-positive infections: current options and beyond. Expert opinion on pharmacotherapy 25 (8) (2024)
Cesare Giulio Passali, Mariaconsiglia Santantonio, Desiderio Passali
The current possibilities of diagnosing and therapies for olfactory disorders. Expert opinion on pharmacotherapy 25 (8) (2024)
Simone Nardin, Gianluca Sacco, Agostina Lagodin D'Amato, Lucrezia Barcellini, Matteo Rovere, Sara Santamaria, Silvia Marconi, Simona Coco, Carlo Genova
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors. Expert opinion on pharmacotherapy 25 (8) (2024)
Simone Nardin, Gianluca Sacco, Agostina Lagodin D'Amato, Lucrezia Barcellini, Matteo Rovere, Sara Santamaria, Silvia Marconi, Simona Coco, Carlo Genova
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors. Expert opinion on pharmacotherapy 25 (8) (2024)
Christian D Harding, Ana Lucia Fuentes, Atul Malhotra
Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance. Expert opinion on pharmacotherapy 25 (8) (2024)

volume 25, number 9, 2024

Noa Rippel, Marina Kremyanskaya
Recent advances in JAK2 inhibition for the treatment of myelofibrosis. Expert opinion on pharmacotherapy 25 (9) (2024)
Denise Battaglini, Ida Giorgia Iavarone, Patricia R M Rocco
An update on the pharmacological management of acute respiratory distress syndrome. Expert opinion on pharmacotherapy 25 (9) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy 25 (9) (2024)
Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease. Expert opinion on pharmacotherapy 25 (9) (2024)
Marco Calcagno, Pietro Serra, Andrea Etrusco, Chrysoula Margioula-Siarkou, Sanjia Terzic, Andrea Giannini, Simone Garzon, Federico Ferrari, Miriam Dellino, Antonio Simone Laganà
A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome. Expert opinion on pharmacotherapy 25 (9) (2024)
Matteo Bassetti, Chiara Sepulcri, Daniele Roberto Giacobbe, Ludovica Fusco
Treating influenza with neuraminidase inhibitors: an update of the literature. Expert opinion on pharmacotherapy 25 (9) (2024)
Noa Rippel, Marina Kremyanskaya
Recent advances in JAK2 inhibition for the treatment of myelofibrosis. Expert opinion on pharmacotherapy 25 (9) (2024)
Tobias Puengel, Frank Tacke
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today? Expert opinion on pharmacotherapy 25 (9) (2024)
Emanuele Dilaghi, Marilia Carabotti, Bruno Annibale
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done? Expert opinion on pharmacotherapy 25 (9) (2024)
Mengdi Zhang, Zhiqiang Wang, Changhai Ding
Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies. Expert opinion on pharmacotherapy 25 (9) (2024)
Megan Z Roberts, Miranda R Andrus
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause. Expert opinion on pharmacotherapy 25 (9) (2024)
Denise Battaglini, Ida Giorgia Iavarone, Patricia R M Rocco
An update on the pharmacological management of acute respiratory distress syndrome. Expert opinion on pharmacotherapy 25 (9) (2024)
Francesco Locatelli, Ernesto Paoletti, Maura Ravera, Giulio Pucci Bella, Lucia Del Vecchio
Can we effectively manage chronic kidney disease with a precision-based pharmacotherapy plan? Where are we? Expert opinion on pharmacotherapy 25 (9) (2024)
Giovanni Battista Dell'isola, Alberto Verrotti, Miriam Sciaccaluga, Roberta Roberti, Lucilla Parnetti, Emilio Russo, Cinzia Costa
Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies. Expert opinion on pharmacotherapy 25 (9) (2024)
Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease. Expert opinion on pharmacotherapy 25 (9) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy 25 (9) (2024)
Megan Z Roberts, Miranda R Andrus
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause. Expert opinion on pharmacotherapy 25 (9) (2024)
Ruth Daunt, Denis Curtin, Denis O'Mahony
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy. Expert opinion on pharmacotherapy 25 (9) (2024)